Epilepsy Medical Cannabis Studies

• View All (505)

Activation of the Cannabinoid Type-1 Receptor Mediates the Anticonvulsant Properties of Cannabinoids in the Hippocampal Neuronal Culture Models of Acquired Epilepsy and Status Epilepticus (2006)

Cannabinoids have anticonvulsant properties, but their effects have not been evaluated in hippocampal neuronal culture models of acquired epilepsy (AD) and status epilepticus (SE). The results of this study represent powerful tools to investigate the molecular mechanisms that mediate the effects of cannabinoids on neuronal excitability. View study
Analysis of endocannabinoid signaling elements and related proteins in lymphocytes of patients with Dravet syndrome (2016)

This study demonstrates that CBD or cannabidiol helps reduce seizures of childhood epilepsy, and dravets syndrome. View study
Assessment of the role of CB receptors in cannabinoid 1 anticonvulsant effects (2001)

It has been shown that cannabinoids are anticonvulsants in the maximum electroshock. This study establishes a role for the CB1 receptor in modulating convulsive activity in an animal model. View study
Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome. (2019)

Epilepsy is one of the most common chronic brain disorders that affects around 70 million people worldwide. The objective of this article was to make a critical review of the pharmacology of Cannabidiol (CBD) and the most recent clinical studies who evaluated its efficacy and safety as a complementary treatment for seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS). View study
Cannabidiol did not induce teratogenicity or neurotoxicity in exposed zebrafish embryos. (2018)

The toxicity studies of Cannabidiol (CBD) are of great importance to ensure the safety of patients. In this context, the morphological analysis of the zebrafish can contribute to evaluate the teratogenic potential, as well as the evaluation of the acetylcholinesterase activity and the motor activity of the zebrafish are valuable tools to verify the potential of neurotoxicity. The results suggest that the effects observed after exposure to CBD are closely related to the CB1 receptor that is present in the zebrafish from the earliest stages of development. View study
Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo (2009)

It is demonstrated that phytocannabinoids have important therapeutic properties, and specifically cannabidiol or CBD has anticonvulsant properties in animal models which highlights its potential as a new antiepileptic drug. View study
Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures (2012)

In this study, cannabidiol is evidenced as a strong candidate to treat human epilepsies, since it reduces the severity of seizures. View study
Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial (2018)

The Lennox-Gastaut syndrome is a severe form of epileptic encephalopathy resistant to conventional treatments. It has been shown that cannabidiol is effective for the treatment of patients with gout attacks associated with Lennox-Gastaut syndrome and is generally well tolerated. View study
Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders (2014)

It has been shown that pure cannabidiol (CBD) has anti-inflammatory and neuroprotective properties. However, studies about the effects of CBD on epilepsy have not been conclusive. For this reason, deeper controlled studies are being planned in target intractable epilepsy populations (in patients with the Dravet and Lennox Gastaut syndromes). View study
Cannabidivarin is anticonvulsant in mouse and rat (2012)

The anticonvulsant profile of cannabidivarin CBDV is investigated for the first time in invitro and in vivo models, demonstrating that it is an effective anticonvulsant without significantly affecting normal motor function. View study
Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism (2013)

Botanical substances (BDS) derived from cannabis, rich in cannabidivarin (CBDV) and cannabidiol (CBD), showed anticonvulsant properties in three crisis models that were not mediated by the CB1 cannabinoid receptor. These findings support the clinical development of CBDV BDS for the treatment of epilepsy. View study
Cannabinoids for pediatric epilepsy? Up in smoke or real science? (2015)

Trials and controlled studies on the effects of cannabidiol in children with epilepsy have shown high quality medical evidence regarding its therapeutic benefits. View study
Cannabinoids in the Treatment of Epilepsy (2015)

Studies in humans suggest that cannabidiol (CBD) and ?9-THC may have beneficial properties for the treatment of epilepsy. However, these studies are quite limited and therefore it is not possible to draw conclusions about them. If randomized clinical trials show that specific cannabinoids are safe and effective, those preparations should be approved and made available. View study
Cannabis, Cannabinoids and Tinnitus (2014)

Cannabinoids exert anti-epileptic effects in various parts of the brain, but the function of CB1 receptors in the circuits of the dorsal cochlear nuclei suggests that cannabinoids may have the potential to facilitate the increase of neuronal excitation rather than inhibit it, which could aggravate tinnitus. However, more in-depth studies of the endocannabinoid system in the cochlear nucleus and other parts of the central auditory system are needed in order to determine whether or not cannabinoids are beneficial in the treatment of tinnitus. View study
CBD-enriched medical cannabis for intractable pediatric epilepsy; The current Israeli experience (2016)

A study was conducted with the objective of confirming the positive effects of medicinal cannabis enriched with cannabidiol (CBD) in children with epilepsy. As a result of this study, 89% of children reported a reduction in the frequency of seizures. However, 7% of patients reported aggravation of seizures that led to abstinence from CBD. In general, these results are very promising. It is necessary to perform more prospective and well designed clinical trials using medicinal cannabis enriched with CBD. View study
Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic Patients (1980)

According to the results of this study, cannabidiol (CBD) has the potential to become an antiepileptic drug, as well as having a possible potentiating effect on other antiepileptic drugs. It was found that CBD has a beneficial effect in patients with secondary generalized epilepsy with temporal focus. View study
Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. (2015)

Refractory epilepsy is when epileptic seizures are so frequent that they limit the patient’s ability to live fully according to their desires and their mental and physical capacity. The objective of this study was under an expanded access investigational new drug (IND) trial, cannabidiol (CBD) is being studied as a possible adjuvant treatment of refractory epilepsy in children. It was concluded that (CBD) is a safe and effective treatment of refractory epilepsy in patients receiving treatment with clobazam (CLB). View study
Duration of use of oral cannabis extract in a cohort of pediatric epilepsy patients (2017)

The results of this study highlight the need for rigorous clinical studies to characterize the efficacy and safety of oral cannabis extracts and their use in the treatment of epilepsy, since despite the legalization of the product in the United States, its effectiveness it is not yet clear. View study
Epidiolex (Cannabidiol) in Treatment Resistant Epilepsy (2015)

This study has obtained promising results for Epidiolex (cannabidiol) as a drug for treatment in children with a variety of epilepsy syndromes. It was found that children and young adults with Dravet’s syndrome had the greatest reduction in seizures. More randomized controlled trials are being conducted to support these results. View study
Marijuana Use in Epilepsy: The Myth and the Reality (2015)

In recent years the interest for the use of cannabinoids for the treatment of epilepsy has grown. This review answers the most significant questions that doctors have about the use of cannabis in the treatment of epilepsy. View study
On the application of cannabis in paediatrics and epileptology (2004)

A study about the therapeutic application of THC in children and adolescents with neurodegenerative diseases, epilepsy and other chronic conditions, showed that THC reduced spasticity, provoked improved dystonia, and had anticonvulsive actions. View study
Redistribution of CB1 Cannabinoid Receptors in the Acute and Chronic Phases of Pilocarpine-Induced Epilepsy (2011)

The endogenous cannabinoid system plays a fundamental role in retrograde synaptic communication and controls the propagation of activity in an epileptic network. Changes in the pattern of CB1 cannabinoid receptor expression are associated with the severity of the hippocampal lesion, caused by acute seizures that eventually lead to sclerosis. View study
Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy (2013)

This study is based on a survey that shows that parents are using cannabis enriched with CBD for the treatment of severe epilepsy in children, and the beneficial effects of this treatment. View study
The case for medical marijuana in epilepsy (2014)

Charlotte is a girl with Dravet syndrome who appeared in a special on CNN. She started a CBD: THC therapy in parallel with her conventional treatment and experienced an extraordinary reduction in the frequency of her seizures. View study

Welcome Back

Create Information

Epilepsy Medical Cannabis Studies